StockData
Summit Therapeutics Inc. logo

Summit Therapeutics Inc. (SMMT) stock

SMMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$10.50−0.17 (-1.59%)

Close on Nov 18, 2026Market cap $8.38BP/E –Yield –

Summit Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Summit Therapeutics's pe ratio was 3.5× on Jan 31, 2022, against 11.0× a year earlier. Over the last 3 years it ranged from 2.0× to 12.7×, with a median of 5.5×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2022Jan 31, 20223.5×−0.8
2021Dec 31, 20214.3×−3.2
2020Dec 31, 20207.5×+4.9
2019Dec 31, 20192.5×–

More Summit Therapeutics figures

See a number that looks wrong?